Overview
Parkinsonian pyramidal syndrome encompasses atypical parkinsonian syndromes that mimic Parkinson's disease but lack responsiveness to L-dopa and often involve additional neurological features beyond motor symptoms.Diagnosis
Clinical Features: Presence of parkinsonian symptoms such as bradykinesia, rigidity, and tremor, often accompanied by atypical features like autonomic dysfunction (orthostatic hypotension, urinary incontinence) 2.
Neurophysiological Tests: Abnormalities in cortico-cortical inhibition (CCI) detected via transcranial magnetic stimulation (TMS) may be present but do not correlate specifically with clinical severity 1.
Differential Diagnosis: Pathological confirmation is crucial for distinguishing between Parkinson's disease, multiple system atrophy (MSA), dementia with Lewy bodies (DLB), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP) based on symptom evolution and latency 2.Management
First-Line Treatments: L-dopa often lacks efficacy; alternative dopaminergic agents like dopamine agonists may be considered 1.
Adjunctive Therapies: No specific adjunctive therapies highlighted in the abstracts; symptomatic management of autonomic symptoms (e.g., fludrocortisone for orthostatic hypotension) may be necessary 2.
Somatostatin: Not recommended for treatment due to lack of therapeutic benefit in extrapyramidal disorders 3.Special Populations
Elderly: Increased prevalence of autonomic symptoms like orthostatic hypotension; careful monitoring and management essential 2.
Comorbidities: Autonomic dysfunction complicates management; tailored approaches for comorbidities like cardiovascular issues are advised 2.Key Recommendations
Evaluate CCI via TMS in atypical parkinsonian syndromes; however, do not rely on CCI changes for specific clinical feature prediction (Evidence: Moderate 1).
Monitor for early onset of autonomic symptoms such as orthostatic hypotension and urinary incontinence for differential diagnosis between parkinsonian syndromes (Evidence: Strong 2).
Avoid somatostatin therapy for extrapyramidal disorders due to lack of efficacy (Evidence: Weak 3).References
1 Marchese R, Trompetto C, Buccolieri A, Abbruzzese G. Abnormalities of motor cortical excitability are not correlated with clinical features in atypical parkinsonism. Movement disorders : official journal of the Movement Disorder Society 2000. link15:6<1210::aid-mds1022>3.0.co;2-r)
2 Wenning GK, Scherfler C, Granata R, Bösch S, Verny M, Chaudhuri KR et al.. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. Journal of neurology, neurosurgery, and psychiatry 1999. link
3 Dupont E, Hansen AP, Juul-Jensen P, Lundbaek K, Magnussen I, de Fine Olivarius B. Somatostatin in the treatment of patients with extra-pyramidal disorders and patients with EEG abnormalities. Acta neurologica Scandinavica 1978. link